Results 221 to 230 of about 79,430 (299)
Reversible Left Ventricular Hypertrabeculation and Hypermetabolism Following Bentall Procedure. [PDF]
Saku K +8 more
europepmc +1 more source
[Studies of oxygen supply and uptake in free skin graft].
G I, Dmitriev, M V, Vogralik
openaire +1 more source
Hepatocellular carcinoma (HCC)‐derived extracellular vesicles (EVs) enrich the metabolic enzyme ATP‐citrate lyase (ACLY). EV‐transferred ACLY enhances palmitate biosynthesis, increases the S‐palmitoylation and stability of multiple immune checkpoint proteins, augments the cellular immunosuppressive activity, and ultimately accelerates the malignant ...
Zhijun Liu +11 more
wiley +1 more source
Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations. [PDF]
Padilla AL +10 more
europepmc +1 more source
This review comprehensively summarizes the atomic defects in TMDs for their applications in sustainable energy storage devices, along with the latest progress in ML methodologies for high‐throughput TEM data analysis, offering insights on how ML‐empowered microscopy facilitates bridging structure–property correlation and inspires knowledge for precise ...
Zheng Luo +6 more
wiley +1 more source
Case Report: Right pulmonary artery resection with artificial vascular graft replacement under cardiopulmonary bypass for pulmonary artery angiomatoid fibrous histiocytoma. [PDF]
Sha T +5 more
europepmc +1 more source
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin +12 more
wiley +1 more source
A new dawn for Parkinson's disease: commentary on the emergence of stem cell-based therapies. [PDF]
Elvira R +4 more
europepmc +1 more source
Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen +13 more
wiley +1 more source

